Arama

EISSN 2148-4279

EJR IS INDEXED IN WEB OF SCIENCE AND PUBMED CENTRAL

European Journal of Rheumatology

PDF

HIGHLY CITED ARTICLES

Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus

Sawalha, Amr H.; Manzi, Susan.

Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg

Crayne, Courtney; Cron, Randy Q.

The emerging role of lung ultrasound in COVID-19 pneumonia

Lepri, Gemma; Orlandi, Martina; Lazzeri, Chiara; Bruni, Cosimo; Hughes, Michael; Bonizzoli, Manuela; Wang, Yukai; Peris, Adriano; Matucci-Cerinic, Marco.

Baricitinib in therapy of COPA syndrome in a 15-year-old girl

Krutzke, Sophia; Rietschel, Christoph; Horneff, Gerd.

New perspectives in the imaging of Raynaud's phenomenon

Herrick, Ariane L.; Dinsdale, Graham; Murray, Andrea.

The contribution of mesenchymal transitions to the pathogenesis of systemic sclerosis

Rosa, Irene; Romano, Eloisa; Fioretto, Bianca Saveria; Manetti, Mirko.

Pediatric Behcet's disease - clinical aspects and current concepts

Yildiz, Mehmet; Koker, Oya; Adrovic, Amra; Sahin, Sezgin; Barut, Kenan; Kasapcopur, Ozgur.

Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation

Miossec, Pierre.

The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia

Cai, Ken; He, Jianna; Wong, Peter K. K.; Manolios, Nicholas.

Characteristics of coexisting localized scleroderma and inflammatory arthritis

Reiff, Daniel; Crayne, Courtney B.; Mannion, Melissa L.; Cron, Randy Q.

All Title Keyword Full Text DOI

Authors

Article Type

Article Category

Year

Search Results

Total of 4 results

Ranking

Release Date Sort Sort Article Type

Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-α agent with a disease-modifying antirheumatic drug?

Döndü Üsküdar Cansu, Sabri Güncan, N. Şule Yaşar Bilge, Timuçin Kaşifoğlu, Cengiz Korkmaz

(Eur J Rheumatol 2014; 1: 62-66) DOI: 10.5152/eurjrheumatol.2014.019

Abstract Full Text (PDF) Related Articles

Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis

Kathleen Tymms, Belinda Butcher, Tegan Smith, Geoffrey Littlejohn, OPAL Consortium

(Eur J Rheumatol 2021; 8: 67-72) DOI: 10.5152/eurjrheum.2020.20024

Abstract Full Text (PDF) Related Articles

The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients

Sinakhanım Huseynzada, Tuba Yüce İnel, Farid Hajiyev, Aydan Köken Avşar, Ali Balcı, Hale Akpınar, Fatoş Önen, İsmail Sarı

(Eur J Rheumatol 2023; 10: 50-56) DOI: 10.5152/eurjrheum.2023.22049

Abstract Full Text (PDF) Related Articles

Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-α agent with a disease-modifying antirheumatic drug?

Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis

The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients

Factors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study